The main aim of this thesis was to assess the efficacy and safety of pasireotide LAR treatment in patients with acromegaly controlled with first-generation somatostatin analogues and pegvisomant.
In chapters 3 and 4 we report the results of the PAsireotide LAR and PEgvisomant study (PAPE) study.
Chapter 5 we assessed whether somatostatin receptor subtype 2 and 5 protein expression correlates and predicts response to pasireotide LAR treatment in the PAPE study.
In chapter 6 we assessed plasma acylated and unacylated ghrelin levels in acromegaly patients using first-generation somatostatin analogues and pegvisomant combination treatment.
Finally in chapter 7 we report the results of a pilot study evaluating whether pegvisomant is expressed in the liver and wheter kupffer cells are involved in the clearance of pegvisomant in two patients with acromegaly.

, , , , , ,
A.J. van der Lelij (Aart Jan) , S.J.C.M.M. Neggers (Bas)
Erasmus University Rotterdam
Department of Reproduction and Development

Muhammad, A. (2019, September 10). Novel Insights in the Modern Medical Management of Acromegaly. Retrieved from